Covance (Princeton, NJ) is increasing its capacity to support specialized sleep studies through a new collaboration with Sleep Medicine Associates. The collaboration gives Covance access to Sleep Medicine Associates’ eight-bed, state-of-the art research facility in Evansville, IN, along with specialized support for studies in restless leg syndrome, insomnia, narcolepsy, fibromyalgia, and other conditions related to the central nervous system.
Covance reports that Board certified sleep expert David Cocanower, MD, of Sleep Medicine Associates, will provide specialized sleep and neurological monitoring and will consult on sleep-specific protocols and study design.
“We are excited to expand our sleep therapeutic expertise, capacity, and recruitment capabilities to better support client needs in this highly specialized area,” said Randall Stoltz, M.D., CPI, medical director, Covance. “Sleep Medicine Associates adds industry-leading expertise and cutting edge technology to Covance’s portfolio.”
Sleep Medicine Associates is fully accredited by the American Academy of Sleep Medicine.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.